期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 47, 期 2, 页码 175-186出版社
WILEY
DOI: 10.1177/0091270006294279
关键词
polymorphic drug metabolism; pharmacogenetics; cytochrome P450; in silica; clinical trial simulation
In vitro-in vivo extrapolation of clearance, embedded in a clinical trial simulation, was used to investigate differences in the pharmacokinetics and pharmacodynamics of dextromethorphan between CYP2D6 poor and extensive metabolizer phenotypes, Information on the genetic variation of CYP2D6, as well as the in vitro metabolism and phormacodynamics of dextromethorphan and its active metabolite dextrorphan, was integrated to assess the power of studies to detect differences between phenotypes. Whereas 6 subjects of each phenotype were adequate to achieve 80% power in showing pharmacokinetic differences, the power required to detect a difference in antitussive response was less than 80% with 500 subjects in each study arm. Combining in vitro-in vivo extrapolation with a clinical trial simulation is useful in assessing different elements of study design and could be used a priori to avoid inconclusive pharmacogenetic studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据